Mice with SQ20B tumour xenografts were treated with GDC-0941 (12.5mg/kg) for three days. At that time, expression of pAkt was determined by immunohistochemistry. Representative images are shown. (n=3, scale bar denotes 100μm). Quantitation of immunohistochemical staining shows significant reduction in pAkt expression (P<0.01).
Treatment with GDC-0941 does not alter tumor volumes

SQ20B xenograft tumor growth measured using ultrasound throughout the time of inhibitor treatment is unaffected by signaling inhibition.
SUPPLEMENTARY FIGURE 3

Doxorubicin half-life is unaffected by pretreatment of tumors with GDC-0941

Mice bearing SQ20B tumors of approximately 300mm$^3$ in size were treated with GDC-0941 (12.5mg/kg) daily for 3 days. At that time doxorubicin (8mg/kg) was given i.p. and at the indicated times plasma samples were collected for determination of doxorubicin concentration. (n=3)

Plasma concentrations of doxorubicin were unaffected by the pretreatment of tumor xenografts with the PI 3-Kinase inhibitor GDC-0941 (12.5mg/kg).